TY  - JOUR
AU  - Segura-Collar, Berta
AU  - Jiménez-Sánchez, Juan
AU  - Gargini, Ricardo
AU  - Dragoj, Miodrag
AU  - Sepúlveda-Sánchez, Juan M
AU  - Pešić, Milica
AU  - Ramírez-González, María A
AU  - Ayala-Hernández, Luis E
AU  - Sánchez-Gómez, Pilar
AU  - Pérez-García, Víctor M
PY  - 2022
DO  - 10.1093/noajnl/vdac155
UR  - http://hdl.handle.net/20.500.12105/15900
AB  - Background: Temozolomide (TMZ) is an oral alkylating agent active against gliomas with a favorable toxicity profile. It is part of the standard of care in the management of glioblastoma (GBM), and is commonly used in low-grade gliomas (LGG). In-silico...
LA  - eng
PB  - Oxford University Press
KW  - In-silico trials
KW  - Mathematical oncology
KW  - Optimal drug scheduling
KW  - Temozolomide resistance
KW  - Tumor phenotype
TI  - On optimal temozolomide scheduling for slowly growing glioblastomas
TY  - journal article
ER  -